Crowdonomics
RespireRx Pharmaceuticals Inc.

Reg A+ · Equity · Aug 2021

ClosedReg A+Equity
via Primary Capital LLC · last checked Aug 16, 2026
Raised
$0 / $7.5M max
0% of ceiling
Investors
—
—
Estimated pre-money
$2.3M
—

Financials disclosed in this offering

FY2020 · hover for source
$0
−$4.3M
FY2020
RevenueNet income
Metric
FY2020 audited
Income statement
Revenue
$0
Cost of goods sold
$2,371,145
Net income
-$4,301,211
Balance sheet
Cash
$825
Accounts receivable
$229,425
Total assets
$85,087
Long-term debt
$332,000
Total liabilities
$8,148,407
Other
Headcount
12

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Dec 1, 2021
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Oct 12, 2021
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$2.3M
Price / share$0.025
Shares offered250,000,000

Estimated, not stated: $0.025 × 90,396,596 securities outstanding.

Offering details

Target—
Max$7,500,000
Min investment—
OpenedAug 9, 2021
Deadline—
Days active1,887

Links & provenance

Source: SEC EDGAR
0001493152-21-018997
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.